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1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in ex-
perimental uremia. Parathyroid cell proliferation and parathyroid hy-
perplasia are features of renal secondary hyperparathyroidism. Since
parathyroids have recently been recognized as an important target for
l,25(OH)2D3, the effects of administration of variable doses of
1 ,25(OH)2D3 on ex vivo radiothymidine incorporation in the parathy-
roid glands, on parathyroid cell mitoses, on parathyroid weight, mor-
phometric indices and on parathyroid protein/DNA ratio were exam-
ined in rats with uremia (subtotal nephrectomy; NX) or with calcium
deficiency. 3H-thymidine incorporation (3 hr; 37°C; PBS with 10 mmol
glucose) was elevated in NX animals, that is, 204 51 dpm/g DNA
versus 96 28 in controls. In vivo pretreatment with I ,25(OH)2D3,
either by intermittent i.p. injection or by osmotic minipump, dose-
dependently decreased 3H-thymidine incorporation and parathyroid
cell mitoses without affecting morphometric indices of parathyroid
cells. Prophylactic administration (i.p.) of I ,25(OH)2D3, starting on the
day of nephrectomy, prevented parathyroid hyperplasia (NX +
1,25(OH)2D3 0.84 g tissue/g body wt vs. 1.25 g in untreated NX and
0.54 in ad libitum fed controls), but 10 days of treatment beginning on
the 21st day of uremia did not reverse existing hyperplasia (NX +
1,25(OH)2D3 1.5 gIg body wt vs. 1.37 g in untreated NX and 0.56 .tg
in ad libitum fed controls). The inhibitory effect was specific for
I ,25(OH)2D3 and not imitated by Dexamethason. However, the effect
was not specific for parathyroid hyperplasia of uremia, since similar
inhibition of 3H-thymidine incorporation by I ,25(OH)2D3 was also
observed in rats on low calcium diet. It is concluded that in experimen-
tal uremia, 1,25(OH)2D3 prevents hyperparathyroidism not only by
diminishing PTH biosynthesis, but also by preventing parathyroid
hyperplasia, and thus potentially basal calcium-independent PTH se-
cretion.
Parathyroid hyperplasia is a hallmark of disturbed calcium
metabolism in renal failure [1, 2]. While the mechanisms
controlling parathyroid hormone (PTH) secretion and biosyn-
thesis have been well elucidated [3, 4], the mechanisms con-
trolling parathyroid cell proliferation and parathyroid gland size
are less clear. Increased parathyroid size is an important aspect
of secondary hyperparathyroidism. Basal calcium-independent
PTH secretion [5] which parallels with increased mass of the
gland, may contribute importantly to elevated circulating PTH
levels in uremic patients.
The role of 1 ,25(OH)2D3 in the control of PTH secretion has
been controversial for a long time. More recently, actions of
Received for publication May 20, 1988
and in revised form November 9, 1988
Accepted for publication November 16, 1988
© 1989 by the International Society of Nephrology
1 ,25(OH)2D3 on half maximal inhibition of PTH secretion by
calcium (set-point) have been described in vitro [5], but definite
evidence for this notion has not yet been provided in vivo,
although existing data are compatible with this possibility [6].
Furthermore, actions of 1 ,25(OH)2D3 on biosynthesis of PTH
[7] have been definitely established. In contrast, the role of
1 ,25(OH)2D3 in preventing parathyroid hyperplasia has not
been well defined. Consequently, the present study was carried
out to determine the effect of I ,25(OH)2D3 on two indices of
parathyroid cell proliferation: radiothymidine incorporation in
parathyroid cells ex vivo and accumulation of mitoses in
colchicin-treated animals in vivo. Recently abnormalities of
1 ,25(OH)2D3 receptor regulation have been recognized in ure-
mia [8, 91. To examine whether the effect was specific for
uremia, separate studies were carried out in rats with secondary
hyperparathyroidism resulting from dietary calcium depriva-
tion.
Methods
Animals
Male Sprague-Dawley rats, 180 to 220 g (Ivanovas Co.,
KisslegglAllgau, FRG) were either sham operated (decapsula-
tion of kidney) or subjected to subtotal nephrectomy under
ether anesthesia. Following surgery, the animals were kept in
single cages in an environment with controlled light on (12 hr)/
light off (12 hr) cycle and with constant temperature (22°C) and
humidity (70%). Animals had free access to Altromin diet C
1000 (Altromin Co., Lage/Lippe, FRG) containing 500 U/kg (13
jig/kg) vitamin D3, 0.95% Ca, and 0.65% Pi (wtlwt). In one
experiment, animals were kept on Altromin diet C 1031 with
0.079% Ca and 0.65% Pi (wt/wt) to induce calcium deprivation.
Protocols
Experiments I and 2. First, we examined parathyroid cell
proliferation (as ex vivo 3H-thymidine incorporation) in animals
with short term and long term uremia and, in addition, evalu-
ated the effects of acute bolus injection of 1 ,25(OH)2D3 prior to
the end of the study.
In one series (designated short term uremia; experiment 1),
the study was terminated after six days and in another series
(designated long term uremia; experiment 2) after three weeks.
To establish the dose response relationship, groups of animals
(N = 10 animals each) were treated 24 hours prior to the end of
experiment 1 with 20, 100 or 500 pmol l,25(OH)2D3 (or propa-
nol as solvent control), given as a single i.p. bolus. To establish
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the time course, cohorts of 10 animals each were studied in a
separate experiment 12 hours, 24 hours and 48 hours after i.p.
bolus injection of l,25(OH)2D3. Animals were weighed and
anesthesized with ether. Parathyroid glands were removed
using microsurgical techniques. Absence of thyroid tissues was
verified histologically in parallel experiments. For incubation
studies with 3H-thymidine, glands were immediately placed in
PBS/glucose (147 mmol Na; 4.1 mmol K; 140 mmol Cl; 11.1
mmol phosphate; 10 mmol glucose; pH 7.4; 4°C). To evaluate
parathyroid weight, parathyroid glands were removed and
weighed on a Mettler H 24 AR balance (Mettler GmbH.,
Giessen, FRG) in a separate series of animals treated with
identical protocol.
For the long term uremia experiment, 20 pmol 1 ,25(OH)2D3
or propanol as solvent was administered i.p. 24 hours prior to
the end of the three week experiment (experiment 2).
Experiment 3. In this study, we evaluated the effects of
uremia and 1 ,25(OH)2D3 administration on parathyroid cell
proliferation by an independent technique, that is counting of
mitosis in parathyroid cells. 200 g male animals were subjected
to sham operation or subtotal nephrectomy (N = 6 per group)
and maintained for three days. One hundred pmol 1 ,25(OH)2D3
(or propanol as solvent) was administered by i.p. injection 48
hours after subtotal nephrectomy, that is, 24 hours prior to the
end of the experiment. Prior to the end of the experiment, four
i.p. injections of 100 jsg colchicin (Demecolcink) or solvent
were given at 30 minute intervals. Animals were subjected to
ether anesthesia. Parathyroid glands were removed and placed
into ice-cold 0.1 M phosphate buffer/3% paraformaldehyde.
Experiment 4. To exclude the possibility that uremia or
1 ,25(OH)2D3 affect the size of parathyroid cells or their nuclei,
detailed morphometric analysis was carried out. To this end,
animals with short term uremia (6 days as in experiment 1) and
sham operated controls were studied. 1 ,25(OH)2D3 (100 pmol)
was administered by i.p. injection 24 hours prior to the end of
the experiment. Each group was comprised of six animals.
Experiment 5. To separately evaluate the effects of intermit-
tent daily administration of 1,25(OH)2D3 on prevention or
reversal of parathyroid hyperplasia, two series of animals were
examined. In one series, uremic animals were treated by daily
i.p. injection of 20 pmol I ,25(OH)2D3 (or propanol as solvent),
starting on the day after nephrectomy until the end of the
experiment, the 10th day of the study (prevention). In the other
series (reversal), animals were left untreated for 21 days after
subtotal nephrectomy or sham operation and thereafter treated
by daily i.p. injection of 20 pmol 1 ,25(OH)2D3 (or propanol as
solvent for a total of 10 days, as in the prevention study). The
experiment was terminated on the 31st day after subtotal
nephrectomy.
Experiment 6. A once daily injection of 1 ,25(OH)2D3 is a
non-physiological maneuver. Therefore, in addition to a once
daily injection as in experiment 5 (first series), we also studied
the effects of administering the same daily dose (20 pmol) as two
daily injections or by osmotic minipump, respectively.
Uremic animals were treated by two daily i.p. injections of 10
pmol 1 ,25(OH)2D3 (= daily dose of 20 pmol) or propanol as
solvent, respectively, starting on the day of nephrectomy until
the end of the experiment on day 10 after nephrectomy. In
parallel, other uremic animals were given 20 pmollday of
1 ,25(OH)2D3 by osmotic minipump (Alzet 2 ML osmotic pump,
Alza Research, Palo Alto, California, USA).
Experiment 7. To examine whether the antiproliferative effect
of I ,25(OH)2D3 was specific for uremia, we also examined rats
with chronic calcium deprivation, another model of hyperpara-
thyroidism, Animals were kept on regular Altromin C 1000 diet
or low calcium Altromin C 1031, and were fed ad libitum with
free access to deionized water. One day prior to the end of the
30 day experiment, groups of seven animals each were given 20
pmol 1 ,25(OH)2D3 (or propanol as solvent) by i.p. injection.
Measurements
Serum creatinine, calcium, phosphate and total protein were
measured with the autoanalyzer technique. 25(OH)D3 was
measured according to Bouillon, Van Kerkhove and de Moor
[10], and 1 ,25(OH)2D3 after Extralut extraction using a radio-
immunoassay [111. Protein was measured according to the
study by Lowry et al [12] and DNA using a modified diphenyl-
amine method according to Burton [13].
Chemicals
Methyl-3H-thymidine (NEN Co., Dreicichenhain, FRG, spe-
cific activity 6.7 Cilmmol), BTS 450 solubilizer and Ready
Organic cocktail were from Beckman Co. (MUnchen, FRG);
radioinert chromatographically pure 1 ,25(OH)2D3 was from
Hoffmann-La Roche Co. (Wyhlen, FRG; courtesy of Dr. Cal-
canis); DNA from calf thymus and bovine serum albumin was
from Sigma Co. (MUnchen, FRG); colchicin as DemecolcinR
(N-Desacetyl-N-methylcolchicin) was from Serva Co. (Heidel-
berg, FRG).
Incubation of parathyroids
Parathyroid glands were removed by microsurgery from 6 or
10 animals and pooled in ice-cold PBS glucose. Subsequently,
the intact glands (12 to 20) were incubated for three hours at
37°C in 1 ml of PBS glucose with 5 Ci 3H-thymidine without
any further manipulation. At the end of the experiment, glands
were extensively washed with PBS and dissolved individually
in 0.5 ml BTS 450 solubilizer for four hours at 40°C and
counted. In some experiments, DNA associated radioactivity
and DNA content were determined; to this end, the washed
glands were ultrasonicated and extracted with 10% TCA (0°C,
30 mm). The TCA precipitate was dissolved in 1 N KOH at 37°C
for 60 minutes. Cold HC 104 was added (final concentration 0.2
M). The resulting precipitate was separated by centrifugation,
washed with 0.2 N HC1O4, hydrolyzed twice by heating (90°C,
20 mm), using 0.2 N HC1O4. The hydrolysates were cooled,
centrifuged and the supernatants were pooled for counting or
for determination of DNA content.
To examine whether the antiproliferative effect of
1 ,25(OH)2D3 was specific for the parathyroids, we also exam-
ined other tissues, that is, slices of liver and spleen and
scrapings of intestinal mucosa (tissue pools of S animals; three
replicate measurements) using animals of the osmotic mini-
pump study (experiment 6).
Measurement of mitotic activity (pretreatment with coichicin)
Specimens were prepared for morphological analysis as de-
scribed previously [9]. Parathyroid glands were carefully ex-
cised, fixed in buffered paraformaldehyde, embedded in para-
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plast, sectioned at 3 to 4 ig and stained with hematoxylin
eosine. Mitoses were counted in four sections of each gland.
Micromorphometric analysis of parathyroids
One parathyroid gland per animal was randomly chosen and
carefully excised for morphometric investigation [14]. All spec-
imens were fixed for 24 hours in ice-cold phosphate buffer (0.1
M) containing 1.5% parafornialdehyde and 1.5% glutaralde-
hyde, subsequently transferred for 30 minutes to 1% Os04 at
room temperature, dehydrated in ethanol and embedded in
epon-araldite. Semithin sections (1 tim) were stained with
methylene blue and basic fuchsin [15], and were examined by
light microscopy using oil immersion and phase contrast tech-
niques.
The volume densities (volume per unit tissue volume) of
epithelial cells V., (e) and interstitial tissue V,, (i), and the
volume density of epithelial cell nuclei V (n) were estimated
by means of the point counting procedure [161. Two random
sections of each parathyroid were selected for morphometry.
The test areas were obtained by random systematic subsamp-
ling. Eight test areas (58,000 tm2) per gland were analyzed with
a Zeiss eyepiece containing 100 test points. Reference volume
was the total volume of the parathyroid.
Mean nuclear volumes (n) were determined as proposed
by Gundersen and Jensen [171. The average of the third power
of observed point-sampled intercept lengths [(l)] multiplied
by irI3 is an unbiased estimator of the mean particle volume in
the volume-weighted distribution of individual particle vol-
umes:
= ir/3 X [(1)J.
Numerical density (Ny) of epithelial cell nuclei cannot be
obtained from two dimensional sections without assumptions
on size and shape of particles. N was estimated according to
the equation [181: N = K X 11/3 X NA 3/2 X where K is
the correction for assumed size distribution of particles (=
1.05); /3 is the shape coefficient (sphere = 1.38, prolate ellipsoid
with axes 2:1:1 = 1.58; prolate ellipsoid with axes 3:1:1 1.95);
and NA is the number of profiles per unit sectional area [16].
Since parathyroid epithelial cell nuclei tend to resemble prolate
ellipsoids with unknown ratios of the axes, we calculated N
for spherical particles Ny(1) and prolate ellipsoid axes 3:1:1;
Nv(2) in order to obtain an estimate for the potential range of
N. From the N estimates of nuclei and V of epithelial cells
we deducted mean epithelial cell volume per nucleus (e)' =
Vv/N,(l) and i'(e)2 = VVINV(2). In the case of mononuclear
epithelial cells this parameter reflects mean cell volume.
Statistics
All data are given as SD. Differences between groups
were examined using Wilcoxon's test for random samples.
Results
Effects of 1,25(OH)2D3 on serum chemistry and on
para thyroid weight or composition in uremic rats
Six days after subtotal nephrectomy, uremic animals had
significantly increased serum creatinine and reduced 1,25
(OH)2D3 levels, despite no change in the concentration of the
precursor 25(OH)D3 (Tables 1 and 2). Compared to sham
operated controls, parathyroid weight was significantly in-
creased with no change in protein or DNA content. Twenty-
four hours after i.p. injection of different concentrations of
l,25(OH)2D3, a significant increase of serum calcium concen-
tration was seen only with the two highest doses of the
secosterole. Parathyroid weight and DNA content were not
significantly affected by l,25(OH)2D3. As shown in Table 2, the
relative contributions of epithelial cells and interstitium as well
as volumes of the nuclei of epithelial cells and the cell volume
per nucleus (which in cells with one single nucleus is equivalent
to total cell volume) were unchanged in uremia. Consequently,
the increase in parathyroid size must reflect parathyroid hyper-
plasia, in agreement with the biochemical finding of unchanged
protein/DNA ratio. Administration of 1,25(OH)2D3 had no
effect on any of these indices.
Effects of 1,25(OH)2D3 on radiothymidine incorporation into
parathyroids of rats with short term or long term uremia
Parathyroid gland weight, normalized for body weight, was
significantly increased in uremic animals with uremia of 6 days
and 3 weeks duration, respectively experiments 1 and 2 (Figs. 1
and 2). In parallel, 3H-thymidine incorporation was increased
when expressed per gland, per mg protein or per mg DNA. A
low dose of 1,25(OH)2D3, 20 pmol or 100 pmol administered 24
hours prior to the end of the experiment by i.p. injection, failed
to affect parathyroid weight (Table 3) or parathyroid morpho-
logical indices (Table 2), respectively, but reduced 3H-thymi-
dine incorporation in the two groups of uremic animals.
The inhibitory effect of 1,25(OH)2D3 on 3H-thymidine incor-
poration was dose-dependent, a pronounced decrement oc-
curring after no more than 20 pmol l,25(OH)2D3. The
time course shows that the effect was rapid, a pronounced decre-
ment occurring 12 hours after i.p. injection. After 20 pmol
1,25(OH)2D3 i.p., serum 1,25(OH)2D3 levels were high in ure-
mic animals at 12 hours, 779 52 pmol/liter versus 560 40 in
controls, and at 24 hours, 519 92 versus 412 50. In vitro
addition of l,25(OH)2D3 (0.5 pmol/ml) did not affect 3H-thymi-
dine incorporation over three hours in parathyroids of control
animals (solvent 96.5 13 dpm/g DNA; 1 ,25(OH)2D3 99 9.4
dpm/g DNA). The effect was specific for the secosterole, since
dexamethasone (0.4 mg/100 g body wt 24 hr prior to the end of
the experiment by i.p. injection) did not decrease 3H-thymidine
incorporation (sham op. no Dex 2228 314 dpm/mg gland;
sham op + Dex 2194 282 dpm/mg gland; uremia no Dex 3110
414 dpmlmg gland; uremia + Dex 3240 314 dpmlmg gland).
No significant effect of uremia was noted on baseline 3H-
thymidine incorporation rates iii spleen (control 1488 118
dpm/mg wet wt; uremia 1769 124) or liver (control 1324 66
dpm/mg wet wt; uremia 1150 55), but a significant increase
was noted in intestinal mucosa (controls 1003 194 dpm/mg
wet wt; uremia 2093 249). Administration of 20 pmol
1 ,25(OH)2D3/day by osmotic minipump for seven days signifi-
cantly (P < 0.01) reduced 3H-thymidine incorporation in all
tissues of uremic animals examined (spleen: 970 79; liver: 687
163; intestinal mucosa 481 60).
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Table 1. Effects of 1 ,25(OH)2D3 on serum chemistry and parathyroid weight or composition in uremic rats
Cr
mg/d!
Ca Pi
Total protein
giliter
25(OH)D3
nmollliter
1 ,25(OH)2D3
pmol/litermmollliter
Control + solvent 0.47 0.02 2.47 0.03 2.6 0.22 60.1 2.5 35 5.5 644 101
+20 pmol 0.49 0.03 2.51 0,06 2.6 0.09 58.8 2.6 31 2.8 653 65
I ,25(OH)2D
+100 pmOl 0.50 0.03 2.54 0.08 3.1 0.23 58.1 1.4
I ,25(OH)2D3
+500 pmol 0.53 0.02 2.66 0.10 3.1 0.11 58.4 3.3
1 ,25(OH)2D3
Uremia + solvent 1.63 010b 2.08 019b 2.3 0.11 53.9 42 4.5 405 41"
+20 pmol 1.69 0,14b 2.35 0.12 2.6 0.4 55.1 2,1b 31 1.2 572 116
1 ,25(OH)2D3
+100 pmol 1.49 018" 2.63 0.15 2.6 0.5 53,4 3.0"
1 ,25(OH)2D3
+500 pmol 1.49 0,18b 2.78 0.16 3.0 0.3 56.1 25b
1 ,25(OH)2D3
N = 10 animals per group; all data are SD.
a one bolus i.p. 24 hrs prior to end of experiment 6 days after subtotal nephrectomy or sham operation
b
significant difference (P < 0.01) between uremic and control animals (Wilcoxon test)
Table 2. Effect of I ,25(OH)2D3 on parathyroid morphology as
evaluated by micromorphometry (experiment 4)
Control +
solvent
(N=6)
Uremia ÷
solvent
(N=6)
Control +
I ,25(OH)2D3(N=6)
Uremia +
I ,25(OH)2D3(N=6)
Vv(e) — vol % 87.7 4.5 87.9 3.6 86.4 2.1 87.1 4.2
V(i) — vol % 12.3 4.5 12.1 3.6 13.6 2.1 12.9 4.2
Vv(n) — vol % l82 3.5 23.2 2.9 15.9 2.6 18.0 1.2
— pm3 91 20 116 23 114 24 136 13
— m3 430 62 471 58 450 100 512 38
V(e)2 — m3 607 88 665 82 635 141 723 54
There were no significant differences between groups.
V(e) volume density of epithelial cells
V(i) volume density of interstitial cells
Vv(n) volume density of epithelial cell nuclei
v(n) mean nuclear volume per unit cell volume of epithelial cells
ce)"2 meanepithelial cell volume per nucleus, assuming spherical (1)
or prolate ellipsoid shape (2) of nucleus respectively
Effect of 1,25(OH)2D3 on mitotic activity in parathyroid
glands of acutely uremic rats
No mitoses were seen in control animals pretreated with
either solvent or 1 ,25(OH)2D3. Mitoses were seen in rats three
days after subtotal nephrectomy, that is, 5.3 0.6 mm2, but
no mitotic activity was seen after pretreatment with
1 ,25(OH)2D3 (experiment 3).
Effect of 10 days administration of 1,25(OH)2D3
prophylactically or therapeutically on parathyroid weight and
radiothymidine incorporation
In animals with prophylactic administration of 1 ,25(OH)2D3,
20 pmol/day by i.p. injection from the time of subtotal nephrec-
tomy, normal values were found for parathyroid weight, protein
or DNA content and 3H-thymidine incorporation. In contrast,
when treatment was started 21 days after subtotal nephrec-
tomy, that is, at a time when considerable hyperplasia had
occurred (Table 1), no significant effect on parathyroid weight
but some reduction of protein content and 3H-thymidine incor-
poration was noted (experiment 5).
To further examine whether the mode of administration of
l,25(OH)2D3 affected its action on parathyroid cells, we also
examined the effect of the same daily amount of 20 pmol of
1 ,25(OH)2D3 administered either as two daily injections i.p. or
by osmotic minipump (experiment 6). As compared with the
once daily injection of 1 ,25(OH)2D3 (Table 4), a similar effect of
twice daily injection or administration by minipump was noted
on weight of parathyroid gland normalized for body weight. The
depression of 3H-thymidine incorporation was more pro-
nounced than with once daily administration (normalized gland
weight: control 0.62 0.05 ig/g body wt; uremia 1.44 0.21;
uremia + 1,25(OH)2D3 twice daily 0.9 0.08; uremia +
1 ,25(OH)2D3 by minipump 0.97 0.11; 3H-thymidine incorpo-
ration: control 2656 328 dpm/mg gland; uremia 4024 381;
uremia + 1 ,25(OH)2D3 twice daily 840 124; uremia plus
1,25(OH)2D3 by minipump 826 165).
Effect of I ,25(OH)2D3 on parathyroid weight and
radiothymidine incorporation in rats on low calcium diet
To further assess whether the effect of l,25(OH)2D3 on
parathyroids was specific for uremia, animals were kept on low
calcium diet for 30 days and then treated with solvent or 20
pmol 1 ,25(OH)2D3 i.p. prior to the end of the experiment
(experiment 7, Table 5). Compared with control diet, animals
on low calcium diet had significantly increased parathyroid
weight with no change of protein/DNA ratio, but unchanged
basal 3H-thymidine incorporation. However, 3H-thymidine in-
corporation was significantly decreased by pretreatment with
1 ,25(OH)2D3, although animals still remained severely hypocal-
cemic.
Discussion
The present study demonstrates that administration of
l,25(OH)2D3 to uremic rats interferes with parathyroid cell
proliferation as assessed with three independent techniques:
analysis of parathyroid weight, measurement of radiothymidine
incorporation and analysis of parathyroid cell mitosis. At least
in short term experiments, 1 ,25(OH)2D3 when given prophylac-
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Table 1. Continued
Final body weight
g
Parathyroid
weight
pg/gland
Normalized
gland wt
gIg body wt
Protein content DNA content
Protein/DNA ratio
p.glp.gpg/mg gland
282 29
286 13
164 12
171 14
0.58 0.04
0.59 0.03
114
102
17.4
14.5
19.5
14.5
2.1
2.2
5.84
5.63
285 25
282 11
216 25"
218 18b
267 27"
254 42"
1.24 0.12"
1.19 0.17*
113
105
19.1
18.3
18.3
18.1
3.4
2.1
6.17
5.80
203 19b
204 33b
N = 10 animals per group; all data are i SD.
a one bolus i.p. 24 hrs prior to end of experiment 6 days after subtotal nephrectomy or sham operation
b
significant difference (P < 0.01) between uremic and control animals (Wilcoxon test)
tically prevented parathyroid hyperplasia, but failed to com-
pletely reverse hyperplasia once the latter had been established.
In the ablation model of uremia, occurrence of parathyroid
hyperplasia (as opposed to hypertrophy) is suggested by un-
changed protein/DNA ratio and by the micromorphometric
findings documenting unchanged sizes of parathyroid cells and
their nuclei. The observation of mitoses in parathyroid glands of
uremic animals, as noted in the present study, further supports
this notion. It is unlikely that the effect of l,25(OH)2D3 was
mediated exclusively by concomitant changes in serum cal-
cium, although Ca concentration is known to affect radiothy-
midine incorporation in parathyroid glands [19]. First, at least at
a dose of 20 pmol, no change in total serum calcium was noted.
Second, in animals with hypocalcemia resulting from low
calcium diet, I ,25(OH)2D3 diminished radiothymidine incorpo-
ration despite serum calcium levels below the normal range.
Fig. 1. Dose response relationship. Abscissa
is dose of l,25(OH)2D3 administered by i.p.
injection 24 hours prior to the end of the
study (experiment I); ordinate is
____________________
radiothymidine incorporation ex vivo into
io 500 parathyroid gland tissue. A. Sham-operated
control animals. B. Subtotally nephrectomized
animals. Each circle represents the
measurement in one tissue pool consisting of
Uremia 18 glands.
The dose response relationship shows that doses which are only
slightly above the estimated daily production rate of
1,25(OH)2D3 in the rat were effective. This observation would
invalidate the argument that the phenomenon reflects on phar-
macological doses beyond the range relevant for therapy in
humans. More physiological modes of administration of
l,25(OH)2D3, such as twice daily injection or osmotic mini-
pump, may prove even more effective in reversing elevated
radiothymidine incorporation rates. Although the issue was not
further pursued, serum l,25(OH)2D3 levels 12 hours and more
after bolus injection of 1 ,25(OH)2D3 were higher in uremic
animals, in line with suggestions, at least by some authors, of
altered metabolism of l,25(OH)2D3 in uremia [20, 21]. We failed
to recover 100% of incorporated 3H-thymidine activity in the
DNA fraction (100% corresponding to the value obtained by
digestion of washed cells), although changes of 3H-thymidine in
BA
200
z
O
0) 100
E0.0
0
0 20 100 500 0
Solvent Solvent
pmol 1,25(OH),D,
Control
pmol 125(OH),D3
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Table 3. Effect of 1 ,25(OH)2D3 20 pmol i.p. on radiothymidine incorporation into parathyroid of rats
(3 weeks) uremia (experiments I and 2)
with short term (6 days) and long term
Cr
mg/dl
.
Ca Pi Normalized
gland wt dpm/mg
mmol/liter jg/g body wt gland
3H-thymidine incorporation
dpm/mg dpm/mg
protein DNA
— control
+solvent 0.41 0.03 2.49 0.06 2.51 0.1 0.56 0.07 2170 314 16200 2320 82340 12000
-l-l,25(OH)2D3 0.48 0.04 2.50 0.08 2.81 0.2 0.53 0.081 1539 214" 11100 14b 58100 8600k'
uremia (6 days)
+solvent 1.78 0.2a 2.22 0.2 2.38 0.4 0.87 0.l2a 3670 550 31300 3695k 171200 25650
+l,25(OH)2D3 1.68 0.14a 2.35 0.12 2.56 0.3 0.76 0.09a 1243 190b 11500 1610" 63130 8830"
—control
+solvent 0.52 0.1 2.42 0.07 2.65 0.3 0.58 0.09 2262 310 19730 2564 116000 16240
+l,25(OH)2D3 0.52 0.14 2.40 0.12 2.42 0.4 0.59 0.14 1069 181b 10450 2120" 59400 10090"
uremia (3 weeks)
+solvent 1.57 0.18k 2.44 0.16 2.35 0.2 1.24 0.lla 3748 562 33100 4965k 204400 30600
+1,25(OH)2D3 1.67 0.12k 2.56 0.21 2.67 0.27 1.19 0.lOa 1283 179" 12200 1708" 71200 100b
N = 25 animals per group. Administration of 20 pmol 1 ,25(OH)2D3 24 hr prior to the end of experiment.
A SD of incubation of at least 10 glands.
Significant difference (P < 0.05) between uremic and control animals (Wilcoxon test)
b Significant difference (P < 0.05) between 1 ,25(OH)2D3 treated and solvent treated animals (Wilcoxon test)
20 pmol
1
.25(OH)203
B
20 pmol
1,25(OH)2D3
0
0 12 24 36 48
Control
Time, hours
0 12 24 36 48
Uremia
Fig. 2. Time course. Abscissa is time after i.p. injection of 20 pmol 1 ,25(OH)2D3 (experiment 1). Ordinate is radiothymidine incorporation into
parathyroid gland tissue. Each circle represents one measurement in a tissue pool of 18 glands.
DNA fraction paralleled changes in washed cells; however,
recovery was similar in uremic animals and controls (data not
shown). It is unknown to what extent incomplete recovery
reflects rapid degradation of newly synthesized DNA or seques-
tration of 3H-thymidine in non-DNA fractions or cell compart-
ments, respectively. Out of concern about incomplete recov-
ery, and to exclude potential effects of 1,25(OH)2D3 on
3H-thymidine uptake or pool size, we decided to validate the
observation by an independent technique, the assessment of the
action of l,25(OH)2D3 on parathyroid cell mitoses. Since
1 ,25(OH)2D3 also suppressed parathyroid cell mitoses in uremic
animals, the results of the radiothymidine experiments were
supported, at least qualitatively by this independent technique.
Incubation of parathyroid glands of control animals with
1,25(OH)2D3 for three hours failed to affect 3H-thymidine
incorporation, but the time course experiment showed that the
suppressive effect on 3H-thymidine incorporation occurred
rapidly within 12 hours. The failure to observe an effect with the
three hour incubation in vitro argues against the notion that the
effect is mediated by non-genomic mechanisms which exhibit a
more rapid time course, such as, via changes in cytosolic
calcium or membrane phospholipid turnover [22]. Vitality of the
gland preparation was verified by demonstration of linear
glucose consumption over the three hour incubation period and
by presence of <2% of surface cells showing Trypan blue
uptake (data not shown).
A
200
z
100
E
0
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Table 4. Parathyroids of uremic animals following daily administration of 20 pmol I ,25(OH)2D3 for 10 days either on day 1 (prevention) or on
day 21 (reversal) after subtotal NX (experiment 5)
Normalized
gland wt Protein content
Protein!
DNA ratio
3H-thymidine incorporation
dpm!mg dpm!mg dpm!mg
p.g!g body wt g!mg gland g!g gland protein DNA
Control 0.54 0.05 104 17.4 5.9 2162 324 19740 2961 116200 17430
Uremia + solvent 1.25 0.15a 102 22.1 6.25 3072 3l3 30420 3420 165400 2l500
Uremia + l,25(OH)2D3 0.84 0.1l' 83 12.7 6.0 2002 290b 20130 2219" 121000 13310"
starting on day I
Control 0.56 0.08 103 15.3 5.41 2084 291 18730 2762 106200 14860
Uremia + solvent 1.37 0.19 99 7.8 5.7 3384 304 31260 3284k 174300 173l0
Uremia + l,25(OH)2D3 1.50 0.14 92 10.1 5.85 990 224" 10100 1313" 59200 7800"
starting on day 21
N = 6 animals per group; all data are SD.
Significant difference (P < 0.05) between uremic and control animals (Wilcoxon test)b Significant difference (P < 0.05) between 1 ,25(OH)2D3 treated and solvent treated animals (Wilcoxon test)
Table 5. Effect of 20 pmol I ,25(OH)2D3 i.p. on radiothymidine incorporation into parathyroid of rats with low Ca diet (experiment 7)
Ca l,25(OH)2D3
.Normalized
gland wt
.Protein!
DNA ratio
3H-tnymiuine incorporation
dpm!mg dpm!mg
mmol!liter pmol!liter g!g body wt jzg!g protein DNA
Control diet
Solvent 2.32 0.08 391 43 0.54 0.081 5.3 20120 2800 110400 16500
l,25(OH)2D3 2.30 0.12 345 25 0.56 0.089 5.4 11300 2130" 60800 12300b
Low calcium diet
Solvent 0.94 0.07 1366 87 1.39 0.l4a 5.4 24900 2650 135700 19800
1,25(OH)2D3 1.02 0.l2a 1228 l03 1.34 0.l2a 5.1 17400 3510" 90300 17000"
N = 7 animals per group; all data are SD; administration of I ,25(OH),D3 24 hrs prior to end of experiment.
a Significant difference (P < 0.05) between control diet and low calcium diet (Wilcoxon test)b Significant difference (P < 0.05) between I ,25(OH)2D3 treated and solvent treated animals (Wilcoxon test)
Reduced specific binding capacity for 1 ,25(OH)2D3 has been
noted in uremic patients [81 and uremic animals [9, 231. Conse-
quently, it is of note that l,25(OH)2D3 acts on parathyroid gland
proliferation. Whether non-subtle quantitative abnormalities of
the dose-response relationship are present cannot be further
evaluated with the present model. The observations in hypo-
calcemic rats on low calcium diet show that the suppressive
action of 1 ,25(OH)2D3 on parathyroid cell proliferation is not
specific for uremia, It is also of note that the inhibitory action of
1,25(OH)2D3 occurred despite high endogenous levels of
1,25(OH)2D3 in animals on low Ca diet. The studies on 3H-
thymidine incorporation in non-parathyroid tissues, that is,
hepatocytes, spleen cells and intestinal mucosa cells show that
the antiproliferative action of 1,25(OH)2D3 is not restricted to
parathyroid cells. This is in agreement with previous observa-
tions in keratinocytes [24], vascular smooth muscle cells [25],
endothelial cells [26, 27], and malignant cell lines [28]. How-
ever, the marked effects of even modest doses of 1,25(OH)2D3
on parathyroid size and weight suggest that the action on
parathyroid cell proliferation is of relevance in vivo.
Our studies do not address the issue by which mechanism
I ,25(OH)2D3 inhibits parathyroid cell proliferation; specifically
the issue has not been resolved whether less parathyroid cell
proliferation is the result of interaction with the gene for
pre-pro-PTH. Studies of Lumb and Stanbury [291 suggest that
relative or absolute deficiency of l,25(OH)2D3 is associated
with more severe hyperparathyroidism. They conclude that
"chronic vitamin D deficiency can greatly intensify the degree
of hyperparathyroidism and determine, thereby, the occurrence
of florid hyperparathyroid bone disease". This notion would
explain the observation of Broadus et al [30]: the greater the
production of l,25(OH)2D3, the more benign primary hyper-
parathyroidism, that is, the less rise in serum calcium, but
greater intestinal absorption of calcium and greater hypercal-
ciuria. Lumb and Stanbury [29] suggest that the relation be-
tween vitamin D status and parathyroid tissue "could be due to
a direct effect of vitamin D deficiency on the parathyroid
tissue", a prediction which is also borne out by the present
experiments. The importance of parathyroid hyperplasia has
been emphasized by Parfitt [31] who analyzed the syndrome of
hypercalcemic hyperparathyroidism following renal transplan-
tation. Signs of parathyroid overactivity, and particularly in-
creased mass of parathyroid glands, tend to persist for months
and years despite normalization of serum calcium and circulat-
ing I ,25(OH)2D3 levels. Reversal of hyperplasia of endocrine
organs is a slow process and occurs only by apoptosis, a
process involving ultrastructural changes of chromatin and
nuclear DNA which is readily distinguishable from cell necrosis
[32]. This consideration led to the postulate of prevention of
parathyroid hyperplasia by prophylactic administration of
1,25(OH)2D3, a strategy which holds more promise than at-
tempts at pharmacological reversal of existing hyperplasia [33,
34]. The contrasting effects of prophylactic and therapeutic
administration of 1 ,25(OH)2D3 in our study are in line with this
postulate.
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